Feridex I.V.Company: Advanced Magnetics
Approval Status: Approved February 1996
Treatment for: liver cancer
Areas: Cancer & Oncology
Feridex I.V. (generic name ferumoxides injectable solution) has been approved as a contrast agent for magnetic resonance imaging (MRI) of liver lesions. Feridex I.V. is the first organ-specific MRI contrast agent to file with the FDA. Through the liver's natural function, the agent is taken up by macrophages found only in healthy liver cells but not in most tumors.
Feridex I.V. is marketed in the United States by Berlex Laboratories. If you have questions regarding Feridex I.V. please contact Berlex Laboratories, Inc. - Department of Epidemiology and Medical Affairs at (800) 888-2407.For product information call (800) 237-5391.
Feridex I.V. is marketed in western Europe by Guerbet S.A. under the tradename Endorem.
Feridex I.V. is marketed in Japan under the tradename Feridex by Eiken Chemical Co., Ltd, in association with Tanabe Seiyaku Ltd.
Feridex I.V. is marketed in Argentina by Temis-Lostal?, in South Korea byTaeJoon Pharmaceuticals, in Israel by Discotrade and in China by Pharmagenesis, Inc.
Feridex I.V. Drug Information
The Feridex I.v. drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.